{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":9,"x_thread":7,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03692065\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"API-CAT","nct_id":"NCT03692065","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=api-cat-nct03692065. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"API-CAT","arms":[{"description":"Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.","label":"Apixaban film coated tablets 2.5 mg","type":"ACTIVE_COMPARATOR"},{"description":"Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.","label":"Apixaban film coated tablets 5 mg","type":"ACTIVE_COMPARATOR"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2024-10-20","type":"ACTUAL"},"conditions":["Cancer-associated Thrombosis"],"enrollment":{"count":1766,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Apixaban 5 MG","type":"DRUG"}],"last_update":"2025-02-06","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","official_title":"Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-09-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"The incidence of an an adjudicated composite endpoint","timeFrame":"During the treatment period (12 months)"}],"references":[{"citation":"Mahe I, Happe F, Monreal M, Robert-Ebadi H, Debourdeau P, Fabreguettes JR, Accassat S, Mismetti P, Girard P, Laporte S, Chapelle C. API-CAT investigators' decisions on anticoagulation following extended treatment for cancer-associated thrombosis. Eur Heart J Cardiovasc Pharmacother. 2026 Sep 22;12(6):447-457. doi: 10.1093/ehjcvp/pvag046.","pmid":"42361291","type":"DERIVED"},{"citation":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P; API-CAT Study Group; API-CAT Investigators. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol. 2026 Jan;13(1):e41-e48. doi: 10.1016/S2352-3026(25)00291-1. Epub 2025 Dec 6.","pmid":"41365312","type":"DERIVED"},{"citation":"Mahe I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, Lopez-Nunez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S; API-CAT Investigators. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025 Apr 10;392(14):1363-1373. doi: 10.1056/NEJMoa2416112. Epub 2025 Mar 29.","pmid":"40162636","type":"DERIVED"}],"start_date":{"date":"2018-10-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"API-CAT STUDY for APIxaban Cancer Associated Thrombosis","url":"https://clinicaltrials.gov/study/NCT03692065"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/api-cat-nct03692065"}